Healthcare / Medical DevicesTel Aviv
$4335.00
-133.00 (-2.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-2.7M · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.6B
P/E
77.4x
↑EV/EBITDA
20810.4x
↑ROE
16.8%
↑Gross Margin
75.3%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+35.0%
FCF CAGR
—
FCF margin
14.6%
FCF / Net income
2.33x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $87.6M · net income $5.5M · FCF $12.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $87.6M | $87.6M | $59.7M | $50.3M | $35.6M |
| Net Income | $5.5M | $5.5M | $-4.5M | $-8.3M | $-19.5M |
| EBITDA | $7.6M | $7.6M | $-2.2M | $-6.6M | $-17.5M |
| EPS | — | — | -0.13 | -0.24 | -0.57 |
| Gross Margin | 75.3% | 75.3% | 76.0% | 74.5% | 73.9% |
| Operating Margin | 7.8% | 7.8% | -6.0% | -15.9% | -48.7% |
| Net Margin | 6.3% | 6.3% | -7.6% | -16.5% | -54.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.06 | 0.05 | 0.06 |
| Current Ratio | 2.43 | 2.43 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $12.8M | $12.8M | $-2.7M | $-6.7M | $-11.1M |
| Returns | |||||
| ROE | 16.8% | 16.8% | -18.5% | -31.4% | -60.4% |
| Valuation | |||||
| P/E | 77.41 | 77.41 | — | — | — |
| EV/EBITDA | 20810.41 | 20810.41 | — | — | — |
| P/B | 4845.27 | 4845.27 | 2122.67 | 2166.72 | 895.42 |
| Growth & Yield | |||||
| Revenue Growth | 46.9% | 46.9% | 18.6% | 41.2% | — |
| EPS Growth | — | — | 45.8% | 57.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+170.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.13 → n/d
Residual
+170.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.